Today: 9 June 2026
Singapore Exchange (SGX) share price slips into weekend — what S68 investors are watching next week
8 February 2026
2 mins read

Singapore Exchange (SGX) share price slips into weekend — what S68 investors are watching next week

Singapore, Feb 8, 2026, 15:10 SGT — The market has wrapped up for the day.

  • Singapore Exchange shares slipped 0.4% to finish at S$17.57 on Friday.
  • Traders are back on Monday, eyes turning to Singapore data and Budget headlines.
  • Most brokers remain upbeat in their notes, though they’re split on how far reforms are actually boosting turnover.

Shares of Singapore Exchange Ltd (S68.SI) slipped 0.4% to close at S$17.57 on Friday, shedding 7 Singapore cents in the final trading session before the weekend. Trading volume hit around 5.0 million shares. The stock wrapped up the day sitting about 3% under its 52-week high, market data showed.

Markets close on Sunday, so attention shifts away from any one company’s headlines. Instead, what matters is how this week shakes out for Singapore’s growth prospects and investor risk-taking. For SGX, it’s simple: higher trading and hedging volumes tend to drive up fee income.

The packed local policy calendar is suddenly a factor, with regional markets on edge once more. When derivatives trading heats up, exchange operators in places like Singapore, Hong Kong, and Japan usually see their shares climb. When things calm down, those same stocks often lose steam.

SGX’s latest earnings report shows adjusted net profit climbed to S$357.1 million for the half-year ended Dec. 31, with net revenue hitting S$695.4 million. The company’s filing also details an interim dividend—11.0 cents per share—set for investors holding shares as of Feb. 13, payable on Feb. 24.

Late Friday, broker notes mostly struck an upbeat tone, though the real question is how long that can last. Maybank Securities’ Thilan Wickramasinghe flagged the fixed income, currencies and commodities arm, or FICC, for its “strong positioning as a risk management venue.” Morningstar’s Roy Van Keulen called derivatives the long-term engine—“not cash equities.” Over at Citi Research, Tan Yong Han kept his sell rating, highlighting the “near-domestic monopoly” fee structure at SGX as a risk if rivals start to challenge. The Edge Singapore

No support from the wider market. Singapore’s benchmark dropped 0.8% Friday, with tech stocks driving losses across Asia. eToro’s Zavier Wong called it “investors de-risking and locking in gains”—not a full-scale shift in sentiment. Reuters

The Ministry of Trade and Industry is set to publish the Economic Survey of Singapore 2025 on Feb. 10 at 8 a.m., with the report detailing fourth-quarter and full-year results, plus figures on inflation, employment, and productivity.

Singapore’s Budget 2026 drops Feb. 12, just two days on, with Bank of America, Maybank, and DBS economists calling for a fiscal surplus somewhere between 0.3% and 1% of GDP, according to Reuters. Bank of America pointed to a likely emphasis on “greater attention to longer-term measures”, while DBS’s Chua Han Teng highlighted “increasingly binding” limits on both land and labor. Reuters

But here’s the catch for the SGX bulls: once volatility drops, trading volumes tend to fall off fast, and a softer interest rate environment threatens to put a dent in treasury income, which props up parts of the operation. If confidence takes a hit—whether it’s a sudden regional selloff, a tech hiccup, or rivals ramping up in derivatives—that recent optimism could get stress-tested in a hurry.

Trading picks back up Monday, and right away, investors’ eyes swing to Tuesday’s Economic Survey and Thursday’s Budget for guidance on local risk appetite. SGX’s Feb. 13 dividend record date sits on the immediate radar too.

Stock Market Today

  • Constant and Constant Advises Piraeus Bank on Safe Bulkers Euronext Athens Dual Listing
    June 9, 2026, 9:51 AM EDT. Constant and Constant Greece and UK firm TLT advised Piraeus Bank on the dual listing of Safe Bulkers, Inc. on Euronext Athens, marking the first Greek shipping company listed in New York to also trade on Athens' exchange. Safe Bulkers, a marine dry bulk carrier with 45 vessels, is now accessible to both U.S. and Greek investors. The legal teams led cross-border due diligence covering loan facilities, guarantees, and fleet agreements to ensure compliance. This move is expected to pave the way for similar listings, enhancing Greece's capital markets. Safe Bulkers' CFO praised the firms for precise, detailed legal support throughout the complex process.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Fortescue share price set for Monday test as Cyclone Mitchell shuts Port Hedland
Previous Story

Fortescue share price set for Monday test as Cyclone Mitchell shuts Port Hedland

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026
Next Story

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026

Go toTop